Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Inmune Bio Inc (INMB)

Inmune Bio Inc (INMB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 109,790
  • Shares Outstanding, K 19,782
  • Annual Sales, $ 160 K
  • Annual Income, $ -30,010 K
  • 60-Month Beta 1.86
  • Price/Sales 686.54
  • Price/Cash Flow N/A
  • Price/Book 2.98
Trade INMB with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( -145.46%)
  • Historical Volatility 72.40%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 196.73% on 09/06/24
  • IV Low 0.00% on 09/18/24
  • Put/Call Vol Ratio 0.25
  • Today's Volume 1,528
  • Volume Avg (30-Day) 190
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 5,838
  • Open Int (30-Day) 4,573

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.39
  • Growth Rate Est. (year over year) +256,253.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.20 +5.19%
on 09/16/24
7.39 -25.98%
on 08/19/24
-1.66 (-23.28%)
since 08/16/24
3-Month
5.20 +5.19%
on 09/16/24
10.05 -45.57%
on 07/16/24
-2.23 (-28.96%)
since 06/18/24
52-Week
5.20 +5.19%
on 09/16/24
14.74 -62.89%
on 02/14/24
-2.32 (-29.78%)
since 09/18/23

Most Recent Stories

More News
INmune Bio, Inc. (INMB) Q2 2022 Earnings Call Transcript

INMB earnings call for the period ending June 30, 2022.

INMB : 5.37 (-3.24%)
INmune Bio, Inc. Announces Second Quarter 2022 Results and Provides Business Update

Company to Host Conference Call Today, August 3, at 4:30pm ET...

INMB : 5.37 (-3.24%)
INmune Bio, Inc. to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, August 3

Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 27, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc....

INMB : 5.37 (-3.24%)
INmune Bio, Inc. CEO, Raymond J. Tesi, MD, to Participate in Two Upcoming Panels on Alzheimer's Disease

Alzheimer's Association International Conference ("AAIC") – Systems Biology of Alzheimer's Disease Panel on August 4, 2022 Moderated by Jeffrey Cummings,...

INMB : 5.37 (-3.24%)
INmune Bio, Inc. Presents Data on Combination Therapy with INB03™ on Overcoming Resistance to HER2 Targeted Therapies in Breast Cancer

In pre-clinical models of trastuzumab resistant MUC4 HER2+ breast cancer, treatment with INB03™ decreases MUC4 expression, reverses resistance to...

INMB : 5.37 (-3.24%)
INmune Bio, Inc. to Provide Additional Manufacturing Information to FDA as Part of IND Application for XPro1595™ in Alzheimer’s Disease

BOCA RATON, FL., May 23, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on...

INMB : 5.37 (-3.24%)
INmune Bio, Inc. (INMB) Q1 2022 Earnings Call Transcript

INMB earnings call for the period ending March 31, 2022.

INMB : 5.37 (-3.24%)
INmune Bio, Inc. Announces First Quarter 2022 Results and Provides Business Update

Company Dosed First Phase 2 Mild Alzheimer’s Disease Patient with Xpro1595; Presented Data from Ongoing INKmune™ Studies Suggesting Increased NK Cell...

INMB : 5.37 (-3.24%)
INmune Bio, Inc. to Report First Quarter 2022 Financial Results and Provide a Corporate Update on Thursday, May 5

Management to host conference call and webcast at 4:30 pm ET on that day...

INMB : 5.37 (-3.24%)
INmune Bio, Inc. to Participate at the B. Riley Neuro & Ophthalmology Conference

Boca Raton, FL, April 25, 2022 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical stage immunology company focused on developing treatments that...

INMB : 5.37 (-3.24%)

Business Summary

INmune Bio Inc. is a clinical-stage biotechnology company. It engages in developing therapies targeting the innate immune system in cancer. The company's product platform consists of INKmune and INB03. INKmune is a natural killer cell therapeutic which primes the patient's NK cells to attack developing...

See More

Key Turning Points

3rd Resistance Point 5.83
2nd Resistance Point 5.72
1st Resistance Point 5.63
Last Price 5.37
1st Support Level 5.43
2nd Support Level 5.32
3rd Support Level 5.23

See More

52-Week High 14.74
Fibonacci 61.8% 11.10
Fibonacci 50% 9.97
Fibonacci 38.2% 8.84
Last Price 5.37
52-Week Low 5.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar